title: [Clinical analysis of 68 patients with primary gastric lymphoma].
abstract: OBJECTIVE
  Stomach is the most common extranodal involvement site of lymphoma. Treatment patterns for primary gastric lymphoma (PGL) are controversial now. This study was to investigate clinical features, treatment patterns, and prognostic factors of patients with PGL.
  
  
  METHODS
  Records of 68 patients with PGL, including 37(54.4%) men,and 31(45.6%) women with a median age of 50(25-82) years,were retrospectively analyzed. Thirty-seven patients received surgery plus chemotherapy,7 received surgery plus chemoradiotherapy,9 received surgery plus radiotherapy,9 received surgery plus chemotherapy, 4 received surgery alone,and 2 were untreated. Survival rate was calculated by Kaplan-Meier method,prognosis factors were analyzed by univariate analysis, and Cox model multivariate analysis.
  
  
  RESULTS
  Common symptoms of PGL were abdominal pain, and weight loss. Common lesions of PGL were in gastric body, and gastric antrum. All 68 patients with PGL were diagnosed of non-Hodgkin's lymphoma (NHL) by pathology, which constituted about 3.4% of all gastric malignancies synchronously, 1 was T cell original, 67 were B cell original. Diagnosis rate of gastroscopy biopsy was 53.2%, that of X-ray barium meal was 40.9%. The overall 1-, 3-, and 5-year survival rates were 90.5%, 78.2%, and 75.7%, respectively. Univariate analysis showed that clinical stage (Ann Arbor), international prognostic index (IPI), and surgery were significant prognostic factors for PGL patients. Cox model multivariate analysis indicated that only surgery was independent prognostic factor for PGL patients.
  
  
  CONCLUSIONS
  Treatment of PGL should be based on combined therapy of surgery, chemotherapy, and radiotherapy. Surgery may be an independent prognostic factor for PGL patients.
authors.affiliation: Department of Medical Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China.
authors.forename: Zhi-Guo
authors.initials: ZG
authors.lastname: Luo
authors.forename: Feng-Yi
authors.initials: FY
authors.lastname: Feng
authors.forename: Pin
authors.initials: P
authors.lastname: Zhang
authors.forename: Xing-Yuan
authors.initials: XY
authors.lastname: Wang
authors.forename: Qi-Lu
authors.initials: QL
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005743:Gastrectomy / Q000379:methods; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D016016:Proportional Hazards Models; D011882:Radiotherapy, High-Energy; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D015996:Survival Rate; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone